Connect your AI

Exagen Inc. XGN Payments Of Debt Issuance Costs

Payments Of Debt Issuance Costs at other companies

RevvityRVTY

——

Biodesix, Inc.BDSX

——

Other financials

Income statement

Revenue$17.3M+11.7%

Gross profit$10.2M+11.9%

Operating income-$3.4M-1.5%

Net income-$4.0M-5.7%

EPS (diluted)-$0.17+15.0%

Balance sheet

Cash & equivalents$21.7M+90.6%

Total debt$27.1M+15.8%

Total equity$14.4M+125%

Total assets$52.0M+28.9%

Cash flow

Operating cash flow-$10.4M+2.4%

CapEx$228.0K+102%

Free cash flow-$10.6M+1.3%

Valuation

Market cap$112.34M-26.5%

Enterprise value$117.78M-20.3%

P/S1.6×-1.0×

Profitability

Gross margin58.3%-1.0pp

Operating margin-20.6%-2.9pp

Net margin-29.5%+2.5pp

FCF margin-27.5%—

Returns & leverage

Return on equity-193.6%+355pp

Debt / equity1.9×-1.8×

Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s payments of debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Exagen Inc.'s payments of debt issuance costs?: Exagen Inc. (XGN) reported payments of debt issuance costs of $0 in Q1 2026.
How has Exagen Inc.'s payments of debt issuance costs changed year-over-year?: Exagen Inc.'s payments of debt issuance costs decreased by 100.0% year-over-year, from $65K to $0.